for educational and safety purposes
Every compound in the sci-wiki that affects gaba-a receptor; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.
5 sourced · 27 reference
Pregnenolone (3β-hydroxypregn-5-en-20-one) is an endogenous neurosteroid and the first steroid synthesized from cholesterol, making it the obligatory precursor of every other steroid hormone, including progesterone, dehydroepiandrosterone (DHEA), cortisol, the sex steroids, and the neuroactive metabolites allopregnanolone and pregnenolone sulfate. Once regarded as a metabolically inert intermediate, it is now recognized as a signaling molecule in its own right, most notably as an endogenous negative allosteric modulator of the type-1 cannabinoid receptor (CB1, the principal brain receptor for THC) and as a ligand for microtubule-associated protein 2 (MAP2, a neuronal cytoskeletal scaffolding protein), through which it promotes microtubule assembly and neurite outgrowth. Synthesized de novo in the brain by neurons and glia, it is investigated as an adjunctive treatment for schizophrenia, mood disorders, and cannabis-related conditions, and is sold over the counter as a nootropic and hormonal supplement.
Dehydroepiandrosterone (DHEA) is an endogenous androstane neurosteroid and the most abundant circulating steroid hormone in humans, secreted chiefly by the adrenal cortex and also synthesized de novo within the central nervous system. It functions primarily as a precursor to androgens and estrogens, yet exerts direct actions on the brain by acting as an agonist at the sigma-1 receptor (an endoplasmic reticulum chaperone protein that shapes calcium and neurotrophic signaling), as a positive modulator of NMDA receptor (the principal excitatory glutamate ion channel involved in learning) signaling, and, chiefly as its sulfate ester DHEAS, as a negative allosteric modulator of the GABA-A receptor (the brain's main inhibitory ion channel). DHEA additionally behaves as a functional anti-glucocorticoid, buffering the neurotoxic effects of cortisol, and shows neuroprotective and mood-related activity in preclinical and clinical studies. Circulating concentrations peak in early adulthood and decline markedly with age, a phenomenon termed adrenopause that has driven its widespread use as an over-the-counter supplement.
Etifoxine (brand name Stresam; also called etafenoxine) is a benzoxazine anxiolytic (an anti-anxiety drug from a chemical family unrelated to the benzodiazepines like Valium). It has been prescribed for the anxious, tense, physical side of stress mainly in France and a handful of other countries since the late 1970s, and it is not approved by the US FDA. What makes it interesting is a dual mechanism: it calms the brain both by directly tuning up GABA-A receptors and by nudging the body to make more of its own calming neurosteroids. In head-to-head trials it eased anxiety comparably to some benzodiazepines while causing less sedation, less memory and psychomotor impairment, and little rebound or dependence when stopped. It has also been explored beyond anxiety for helping injured peripheral nerves heal and for damping neuroinflammation (inflammation inside nervous tissue). The important caveat is safety: rare but serious liver injury and severe skin reactions have been reported.
Pregnanolone (3α-hydroxy-5β-pregnan-20-one, also written 3α,5β-tetrahydroprogesterone) is an endogenous neurosteroid, meaning a steroid that acts rapidly on neuronal ion channels rather than through classical intracellular hormone receptors, formed as a reduced metabolite of progesterone. It is the 5β epimer of allopregnanolone and a potent positive allosteric modulator of the GABA-A receptor (the pentameric chloride channel that carries most fast inhibitory signalling in the brain), giving it sedative, anxiolytic, anticonvulsant and anaesthetic properties. Under the International Nonproprietary Name eltanolone it was developed in the 1990s as an intravenous general anaesthetic, formulated in a soybean-oil emulsion after earlier castor-oil-solubilised steroid anaesthetics proved allergenic; smooth induction and cardiovascular stability were offset by slow recovery and skin reactions, and it was never marketed. Its sulfate and synthetic glutamate esters are studied separately as use-dependent inhibitors of the NMDA receptor, an excitatory glutamate channel implicated in excitotoxicity and neuroprotection.
Progesterone (P4; pregn-4-ene-3,20-dione) is an endogenous pregnane steroid hormone best known for its reproductive roles and is the prototypical neuroactive precursor within the neurosteroid system. Although the parent hormone signals principally through classical nuclear progesterone receptors and through membrane-associated receptors such as PGRMC1 and the mPR/PAQR family, most of its rapid effects on neuronal excitability arise only after sequential metabolism to 5-alpha-dihydroprogesterone and then to allopregnanolone, one of the most potent endogenous positive allosteric modulators of the GABA-A receptor (the brain's principal inhibitory chloride channel). Progesterone and its metabolites are synthesized within the nervous system itself, where they regulate myelination, neuronal survival, neuroinflammation, and inhibitory tone. It has been studied extensively as a neuroprotective agent, with strong preclinical support but negative large-scale human trials in acute traumatic brain injury.
3α-Androstanediol (5α-androstane-3α,17β-diol) is an endogenous neurosteroid formed as the terminal 3α-reduced metabolite of dihydrotestosterone (DHT, the most potent natural androgen). Despite its androgenic origin it binds the androgen receptor only weakly; its defining pharmacology is potent positive allosteric modulation of the GABA-A receptor (the brain's principal inhibitory chloride ion channel), which produces anxiolytic (anxiety-reducing) and anticonvulsant (seizure-suppressing) effects in animal models. It is widely regarded as the androgenic counterpart of allopregnanolone (the analogous progesterone-derived neurosteroid), and is proposed to mediate much of the influence that testosterone exerts on seizure threshold, anxiety, and mood in males. It additionally acts as a ligand of estrogen receptor beta (ERβ), which may underlie some of its cognitive and neuroprotective actions.
5α-Dihydroprogesterone (5α-DHP) is an endogenous neurosteroid and progestogen formed when the enzyme 5α-reductase reduces progesterone at the A-ring of the steroid nucleus, yielding 5α-pregnane-3,20-dione. It occupies the committed first step of the principal neurosteroid pathway, standing between progesterone and allopregnanolone (its 3α-hydroxylated metabolite and one of the most potent naturally occurring positive modulators of the GABA-A receptor, the brain's main inhibitory ion channel). Unlike allopregnanolone, 5α-DHP is itself a high-affinity agonist of the classical (nuclear) progesterone receptor, driving progesterone-responsive gene transcription; in horses it is a fully biopotent progesterone receptor agonist that sustains the second half of pregnancy after circulating progesterone becomes undetectable. It is synthesized in situ within neurons and glia of the central and peripheral nervous systems, where its production rises after nerve injury and falls under chronic stress.
Alfaxalone (also spelled alphaxalone) is a synthetic neuroactive steroid of the pregnane class that produces general anesthesia by acting as a positive allosteric modulator (a molecule that amplifies a receptor's response to its own neurotransmitter) at the GABA-A receptor, the principal inhibitory ion channel of the central nervous system. First introduced in 1971 as the main active component of the intravenous anesthetics Althesin (human) and Saffan (veterinary), it was withdrawn from human use in the 1980s because the solubilizing vehicle Cremophor EL provoked anaphylactoid reactions, then reintroduced in a cyclodextrin formulation marketed for veterinary anesthesia as Alfaxan. Because it lacks classical hormonal activity yet retains rapid, non-cumulative central depressant effects, alfaxalone occupies a distinct pharmacological niche among intravenous anesthetics and now serves as a template for a new generation of water-soluble neurosteroid sedatives such as Phaxan.
Allopregnanolone (chemically 3-alpha-hydroxy-5-alpha-pregnan-20-one, also known as 3-alpha,5-alpha-tetrahydroprogesterone or 3-alpha,5-alpha-THP) is an endogenous neurosteroid synthesized in the brain, adrenal glands and gonads as a downstream metabolite of the hormone progesterone. It is the prototypical inhibitory neuroactive steroid and one of the most potent known positive allosteric modulators (molecules that amplify a receptor's response to its natural transmitter) of the GABA-A receptor (the brain's principal inhibitory chloride ion channel), acting at both synaptic receptors and extrasynaptic delta-subunit-containing receptors. The pharmaceutical formulation of this exact molecule, brexanolone (trade name Zulresso), became in 2019 the first drug ever approved by the United States Food and Drug Administration specifically for postpartum depression, and its orally active analog zuranolone followed in 2023. Beyond its rapid actions on inhibitory neurotransmission, allopregnanolone participates in the stress response, ovarian-cycle and pregnancy physiology, seizure regulation and, as more recently characterized, the suppression of innate-immune inflammatory signaling.
Allotetrahydrocorticosterone (3α,5α-tetrahydrocorticosterone, or allo-THB) is an endogenous neurosteroid generated by sequential 5α-reduction and 3α-hydroxylation of the adrenal glucocorticoid corticosterone. It is the corticosterone-derived structural counterpart of THDOC (which is formed the same way from deoxycorticosterone) and behaves as a positive allosteric modulator (an enhancer that boosts a receptor's response without activating it directly) of the GABA-A receptor (the brain's principal inhibitory chloride ion channel); the additional 11β-hydroxyl group it carries, however, makes it a considerably weaker potentiator than THDOC or allopregnanolone. Beyond GABA-A it shows an unusually broad ion-channel profile, inhibiting glycine receptors (a second inhibitory chloride channel, prominent in the brainstem and spinal cord) and N-type calcium channels (presynaptic channels that gate neurotransmitter release), opening large-conductance calcium-activated potassium channels (BK or Maxi-K channels) in sensory nerves, and retaining residual glucocorticoid-receptor agonism. Clinically it appears mainly as a minor urinary corticosteroid metabolite that indexes 5α-reductase activity in steroid profiling.
Alphadolone (alfadolone; clinically alphadolone acetate) is a synthetic neuroactive pregnane steroid (a laboratory-made steroid that acts on the nervous system) which potentiates the GABA-A receptor, the brain's principal fast inhibitory chloride channel, to produce sedation and anaesthesia. It is best known as the minor component of the intravenous anaesthetic Althesin (for humans) and Saffan (for animals), where it was combined with the more potent alfaxalone in a 3:1 ratio, added chiefly to improve the poor water solubility of alfaxalone while still contributing roughly half of that agent's anaesthetic potency in its own right. Both preparations were dissolved in the surfactant Cremophor EL, whose tendency to trigger histamine release and anaphylactoid reactions led to the withdrawal of Althesin from human use in 1984. Alphadolone later attracted independent research interest because, unlike alfaxalone, it produces spinally mediated analgesia without sedation when given by mouth or intraperitoneally, an effect thought to depend on an analgesic metabolite formed in the liver.
Androstenol (5-alpha-androst-16-en-3-alpha-ol, with a 3-beta epimer) is an endogenous 16-androstene steroid (a C19 steroid that lacks the C-17 oxygen of typical androgens) and a putative human chemosignal. It is synthesized alongside testosterone in the testis, secreted in axillary (underarm) sweat, and also occurs as a major aroma component of truffles, where its volatile, musky odor is biologically active. Its documented neuroactivity in humans is chemosensory; smelling androstenol has been reported to shift self-rated mood and social judgments in some experiments and to activate the anterior hypothalamus in women, although rigorous reviews consider the evidence for a true human pheromone effect weak and inconsistent. It is grouped with the neurosteroids because it is a steroid with measurable central chemosensory and neuroendocrine effects, not because a defined ion-channel mechanism has been established.
Androsterone (3α-hydroxy-5α-androstan-17-one) is an endogenous androstane neurosteroid (a steroid synthesized or acting within the nervous system) and a peripheral metabolite of testosterone and dehydroepiandrosterone. Like its pregnane counterpart allopregnanolone, it acts as a positive allosteric modulator (an agent that enhances a receptor's response to its natural transmitter) of the GABA-A receptor (the brain's principal inhibitory ion channel), producing barbiturate-like potentiation of inhibitory neurotransmission. In rodent studies it raises seizure threshold across multiple models and is regarded as an endogenous modulator of neuronal excitability; because native androsterone is rapidly conjugated and orally poorly available, a prodrug (an inactive precursor that converts to the active drug in the body) has been investigated for epilepsy.
Deoxycorticosterone (11-deoxycorticosterone, 21-hydroxyprogesterone; also called cortexone or desoxycortone) is an endogenous steroid hormone made by the adrenal cortex that functions both as a mineralocorticoid and as the metabolic precursor to a potent neurosteroid. Acting through the mineralocorticoid receptor (a ligand-activated transcription factor that governs sodium and water balance), it promotes renal salt retention with an affinity close to that of aldosterone. Its principal relevance to neuropharmacology is as the parent compound of 3-alpha,5-alpha-tetrahydrodeoxycorticosterone (THDOC), a positive allosteric modulator of the GABA-A receptor (the brain's main inhibitory chloride channel) that is released during stress and shapes seizure threshold, anxiety, and hypothalamic-pituitary-adrenal (HPA) axis activity. Deoxycorticosterone should not be confused with the psychedelic amphetamine also abbreviated DOC (2,5-dimethoxy-4-chloroamphetamine), which is an entirely unrelated compound.
DHEA sulfate (DHEAS) is the 3-beta sulfate ester of dehydroepiandrosterone and the most abundant circulating steroid in the human body, present in plasma at concentrations roughly a thousandfold higher than unconjugated DHEA. Synthesized principally in the zona reticularis of the adrenal cortex, it functions as a stable, long-lived reservoir that is interconverted with DHEA and supplies a precursor pool for downstream androgens and estrogens. Within the nervous system it is classified as a neurosteroid (a steroid synthesized in or acting directly upon nervous tissue); it acts as an agonist at the sigma-1 receptor (an intracellular chaperone protein), a positive modulator of the NMDA receptor (a glutamate-gated excitatory ion channel), and a negative allosteric modulator of the GABA-A receptor (the brain's principal inhibitory ion channel), giving it a net excitatory, pro-cognitive neuromodulatory profile. Circulating concentrations fall markedly with age, a decline termed adrenopause that has made DHEAS a widely studied biomarker of adrenal function, cognitive aging, and longevity.
Emapunil (developmental codes XBD-173 and AC-5216) is an investigational anxiolytic that acts as a selective, high-affinity agonist of the 18-kDa translocator protein (TSPO), a mitochondrial cholesterol-transport protein once known as the peripheral or mitochondrial benzodiazepine receptor. Rather than binding the central benzodiazepine site itself, emapunil stimulates the brain's own synthesis of neurosteroids, most notably allopregnanolone, which then potentiate GABA-A receptors (the brain's main inhibitory chloride channels) to produce anxiolysis. In a landmark 2009 human panic-provocation study it reduced induced anxiety without the sedation, tolerance, or withdrawal that characterise benzodiazepines. It reached Phase 2 clinical evaluation before development was discontinued, and it remains a widely cited proof of concept for neurosteroid-based anxiolysis.
Epiandrosterone (3β-hydroxy-5α-androstan-17-one; also called isoandrosterone) is an endogenous 5-alpha-reduced steroid formed from dehydroepiandrosterone (DHEA) and androstenedione, and it is the 3-beta-hydroxyl epimer of androsterone. It circulates in humans predominantly as its sulfate ester and functions as a weak neurosteroid (a steroid that acts on neuronal receptors rather than classical nuclear hormone receptors), producing only mild modulation of the GABA-A receptor (the brain's principal inhibitory chloride ion channel) while inhibiting glycine receptors (another inhibitory ligand-gated channel concentrated in the spinal cord and brainstem). Beyond the nervous system it is a well-characterized uncompetitive inhibitor of glucose-6-phosphate dehydrogenase (G6PD, the rate-limiting enzyme of the pentose phosphate pathway) and a recognized urinary marker of 5-alpha-reductase activity. Because it can be metabolized toward dihydrotestosterone (DHT, the most potent natural androgen), it is also sold over the counter as a non-methylated androgen prohormone.
Epipregnanolone (3beta-hydroxy-5beta-pregnan-20-one) is an endogenous neurosteroid and the fourth stereoisomer of tetrahydroprogesterone, distinguished from allopregnanolone (3alpha,5alpha), pregnanolone (3alpha,5beta), and sepranolone (3beta,5alpha) by its combined 3beta-hydroxyl group and 5beta (cis) ring fusion. It is a ring A-reduced metabolite of progesterone that, unlike the sedative potentiators allopregnanolone and pregnanolone, was classically characterized as a selective antagonist at the neurosteroid modulatory site of the GABA-A receptor (the brain's principal inhibitory ion channel), blocking their potentiation without altering the response to GABA itself. Its 3-sulfate ester is a negative allosteric modulator of the NMDA receptor (a glutamate-gated excitatory channel), and the parent steroid is also a potent blocker of CaV3.2 T-type calcium channels, giving it a profile that is unusually distinct from its potentiating sister isomers. Present at low concentrations in human plasma, especially around parturition, and producible by human gut bacteria, epipregnanolone is studied primarily as a pharmacological tool and a scaffold for neurosteroid drug design rather than as a therapeutic or supplement.
Etiocholanolone (3α-hydroxy-5β-androstan-17-one) is an endogenous androstane neurosteroid formed as a major hepatic metabolite of testosterone and androstenedione. It is the 5-beta epimer of androsterone and acts as a positive allosteric modulator (a compound that amplifies a receptor's response to its own natural ligand) of the GABA-A receptor (the brain's principal inhibitory chloride channel), where it enhances inhibitory neurotransmission and produces anticonvulsant effects in animal seizure models. Etiocholanolone is equally notable in classical human physiology as one of the first identified endogenous pyrogens; injection of the unconjugated steroid reliably produces fever by prompting leukocytes to release interleukin-1. It possesses negligible androgenic activity and circulates largely as biologically inactive glucuronide and sulfate conjugates.
Ganaxolone (research code CCD-1042; brand name Ztalmy) is a synthetic neuroactive steroid, specifically the 3-beta-methyl analog of the endogenous neurosteroid allopregnanolone (a metabolite of progesterone). It is a positive allosteric modulator (a molecule that amplifies a receptor's response to its natural activator) of the GABA-A receptor, the brain's principal inhibitory chloride channel, and it enhances both synaptic (phasic) and extrasynaptic (tonic) inhibition, with particularly strong activity at delta-subunit-containing receptors. In March 2022 it became the first medicine approved by the United States Food and Drug Administration for seizures associated with CDKL5 deficiency disorder (a rare genetic developmental and epileptic encephalopathy caused by mutations in the cyclin-dependent kinase-like 5 gene), and the first synthetic neurosteroid approved as an anticonvulsant. The defining 3-beta-methyl group makes ganaxolone orally bioavailable, metabolically stable, and non-hormonal, distinguishing it from its parent neurosteroid, which requires intravenous administration.
Homotaurine, chemically 3-amino-1-propanesulfonic acid (3APS), is a small aminosulfonic acid that occurs naturally in certain marine red algae; it is a homolog of the amino acid taurine and a structural analog of the inhibitory neurotransmitter GABA, and it behaves as a GABA-A receptor modulator. Its pharmaceutical interest, however, comes from a different property: it is an anti-amyloid agent that binds soluble amyloid-beta and inhibits its aggregation into neurotoxic oligomers. Under the drug name tramiprosate it was carried into large phase 3 Alzheimer's disease trials that were negative overall, yet a subgroup signal tied to the APOE4 genotype survived the failure and drove a second act. That signal spawned a valine-conjugated prodrug, ALZ-801 (valiltramiprosate), now studied specifically in APOE4/4 homozygotes with early Alzheimer's disease. Homotaurine is also sold as a nutraceutical for memory, where its efficacy remains unproven.
Hydroxydione is a synthetic pregnane neuroactive steroid that, introduced by Pfizer in 1955 under the trade name Viadril (also Presuren), became the first steroid used as an intravenous general anesthetic. The parent steroid, 21-hydroxy-5-beta-pregnane-3,20-dione, is almost insoluble in water; esterifying its 21-hydroxyl group with succinic acid and forming the sodium salt yields hydroxydione sodium succinate, a water-soluble prodrug that plasma esterases (enzymes that cleave ester bonds) hydrolyze in vivo to release the active steroid. Like later neurosteroid anesthetics such as alfaxalone, it produces hypnosis by acting as a positive allosteric modulator of the GABA-A receptor (the brain's principal inhibitory chloride ion channel), without meaningful analgesic or classical hormonal activity. Although valued for a wide margin of cardiovascular and respiratory safety, its very slow onset and a high incidence of injection-site thrombophlebitis (painful inflammation and clotting of the vein) led to its abandonment, yet it remains historically pivotal as the origin of the entire field of steroid anesthesia.
Minaxolone is a synthetic water-soluble aminosteroid (a steroid carrying a basic amino group) developed by Glaxo in the late 1970s as an intravenous general anaesthetic and a successor to Althesin. Structurally it is a 2-beta-ethoxy, 11-alpha-(dimethylamino) derivative of the neuroactive pregnane skeleton, and it acts as a potent positive allosteric modulator at the neurosteroid recognition site of the GABA-A receptor (the brain's principal inhibitory chloride ion channel), enhancing inhibitory conductance to produce hypnosis and surgical anaesthesia. Its basic amino group conferred solubility in water, avoiding the Cremophor EL vehicle (a polyethoxylated castor oil solubiliser) that made earlier lipophilic steroid anaesthetics prone to anaphylactoid reactions. After clinical trials conducted between roughly 1979 and 1982, its development was halted over toxicity and genotoxicity concerns arising in long-term rodent studies, and it was never marketed.
Org 20599 is a synthetic water-soluble aminosteroid general anaesthetic developed by Organon in the 1990s as a member of the 2-beta-morpholinyl pregnane class. Chemically it is (2beta,3alpha,5alpha)-21-chloro-3-hydroxy-2-(4-morpholinyl)pregnan-20-one, usually handled as its methanesulphonate (mesylate) salt, and it retains the 3-alpha-hydroxy, 5-alpha-reduced pregnane pharmacophore that defines the natural neurosteroid anaesthetics such as alphaxalone and allopregnanolone. Its principal action is positive allosteric modulation of the GABA-A receptor (the brain's main inhibitory chloride ion channel), with additional direct channel activation (GABA-mimetic agonism) at higher concentrations. It produced rapid-onset, short-duration anaesthesia in rodents but was never marketed; its close analogue Org 21465 reached Phase I human trials and caused excitatory involuntary movements in every volunteer, and the class was discontinued.
Org 21465 (also written ORG-21465) is a water-soluble aminosteroid intravenous anaesthetic developed by Organon in the 1990s as a companion candidate to the earlier compound Org 20599. It belongs to a series of 2-substituted (C2-morpholinyl) pregnane steroids engineered to combine the favourable receptor pharmacology of neuroactive steroids with the aqueous solubility needed for a practical injectable formulation, acting principally as a positive allosteric modulator (an agent that amplifies a receptor's response without being the primary trigger) of the GABA-A receptor (the brain's main inhibitory chloride ion channel). In computer-controlled infusion studies in healthy male volunteers the compound produced dose-related sedation and reversible loss of consciousness, but it was accompanied by prominent involuntary excitatory movements, injection-site venous pain, and slow equilibration with the effect site, and its clinical development was subsequently abandoned. It survives in the literature as a historical, niche illustration of the difficulty of translating neurosteroid GABA-A pharmacology into a usable anaesthetic.
Pregnenolone sulfate (PregS) is an endogenous excitatory neurosteroid (a steroid synthesized in and acting upon the nervous system) formed by sulfation of pregnenolone at its 3beta-hydroxyl group. It is among the most intensively studied neurosteroids in ion-channel pharmacology, acting simultaneously as a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptors that contain GluN2A or GluN2B subunits (the principal glutamate-gated channels underlying synaptic plasticity), a negative allosteric modulator of GABA-A receptors (the brain's main inhibitory chloride channels), a low-affinity agonist of the sigma-1 receptor (an intracellular chaperone protein) and the prototypical agonist of the TRPM3 cation channel. Through these convergent actions it enhances glutamatergic transmission, hippocampal acetylcholine release, long-term potentiation and memory consolidation in animal models, which underlies its reputation as a pro-cognitive neurosteroid. Its physiological concentrations, and even its unambiguous presence in mammalian brain, remain debated, so much of the evidence base derives from experimental administration rather than demonstrated endogenous signaling.
Renanolone (3alpha-hydroxy-5beta-pregnane-11,20-dione) is a synthetic pregnane steroid that was investigated as an intravenous general anaesthetic during the Glaxo steroid-anaesthetic program of the 1960s and 1970s. It is the 5beta-configured epimer of alphaxalone (alfaxalone), differing only in the stereochemistry of the A/B ring fusion, and it belongs to the same 3alpha-hydroxy-pregnane pharmacophore that defines neurosteroid modulators of the GABA-A receptor (the brain's principal inhibitory chloride ion channel). Like other steroid anaesthetics it produces sedation, hypnosis and anaesthesia by acting as a positive allosteric modulator of GABA-A receptors, although modern photoaffinity work shows it occupies the intersubunit neurosteroid pocket roughly twenty times more weakly than its 5alpha counterpart. Never marketed, it survives as a historical and mechanistic reference compound within the neurosteroid anaesthetic class.
SAGE-324 (also designated BIIB124) is an investigational, orally bioavailable synthetic neuroactive steroid that acts as a positive allosteric modulator (a compound that amplifies a receptor's response to its natural signal) of GABA-A receptors (the brain's principal inhibitory chloride ion channels). Developed on the Sage Therapeutics neuroactive-steroid platform and co-developed with Biogen, it is a next-generation analog engineered for a long duration of action suitable for once-daily oral dosing, distinguishing it from the intravenous and short-acting neurosteroids that preceded it. Its lead clinical indication is essential tremor (a common movement disorder marked by rhythmic shaking of the hands and arms), where the randomized Phase 2 KINETIC trial met its primary endpoint; it has also been explored in the context of epilepsy. As a synthetic congener within the same chemical lineage as brexanolone and zuranolone, SAGE-324 represents an effort to translate the potent inhibitory pharmacology of endogenous neurosteroids into a chronically dosable oral therapeutic.
Sepranolone (isoallopregnanolone; 3beta-hydroxy-5alpha-pregnan-20-one) is an endogenous pregnane neurosteroid that is the 3beta-epimer of allopregnanolone, differing only in the spatial orientation of a single hydroxyl group at carbon 3. Whereas allopregnanolone is one of the most potent known positive modulators of the GABA-A receptor (the brain's principal inhibitory chloride ion channel), isoallopregnanolone possesses no intrinsic modulatory activity of its own and instead acts as a selective functional antagonist that reverses allopregnanolone's enhancement of GABA-A signalling without touching the benzodiazepine site, the barbiturate site, or the basal GABA response. Under the development name UC1010 it has been advanced by Asarina Pharma as a subcutaneously administered candidate for premenstrual dysphoric disorder (PMDD) and related menstrually entrained and compulsive conditions, reaching Phase 2 clinical testing. It represents the prototype of a drug class termed GAMSA (GABA-A receptor modulating steroid antagonists).
THDOC (3-alpha,5-alpha-tetrahydrodeoxycorticosterone) is an endogenous neurosteroid (a steroid that acts rapidly on neuronal membrane receptors rather than on classical nuclear hormone receptors) and the fully reduced 3-alpha,5-alpha metabolite of the adrenal steroid deoxycorticosterone. It is one of the most potent naturally occurring positive allosteric modulators (compounds that amplify a receptor's response to its own transmitter) of the GABA-A receptor, the brain's principal inhibitory chloride ion channel, where it enhances both fast synaptic and sustained extrasynaptic inhibition. Because its synthesis is driven by adrenocorticotropic hormone and by acute stress, THDOC is regarded as a stress-responsive inhibitory neurosteroid that provides negative feedback on the hypothalamic-pituitary-adrenal axis and transiently raises the seizure threshold. Alongside allopregnanolone, it is a prototypical member of the stress-derived GABAergic neurosteroid family.
Zuranolone (development code SAGE-217; marketed as Zurzuvae) is an orally bioavailable synthetic analog of allopregnanolone (a naturally occurring neurosteroid derived from progesterone) that acts as a positive allosteric modulator (a compound that amplifies a receptor's response to its own transmitter) of the GABA-A receptor (the brain's principal inhibitory chloride channel). It was engineered by Sage Therapeutics from the same neurosteroid scaffold as the intravenous agent brexanolone, but with a modified 3-hydroxy pyrazole substitution that confers metabolic stability suitable for once-daily oral tablets rather than a continuous infusion. In August 2023 the United States Food and Drug Administration approved zuranolone for postpartum depression (a major depressive episode arising in the weeks after childbirth), making it the first oral drug indicated specifically for that condition. It is notable for producing an antidepressant response within days when given as a short, fixed two-week course, in contrast with the weeks-long onset of conventional monoamine antidepressants.
Zaleplon is a nonbenzodiazepine hypnotic of the pyrazolopyrimidine class, one of the so-called Z-drugs used for the short-term treatment of insomnia. It was approved in the United States in 1999 and is sold under brand names including Sonata. Because it has an unusually short duration of action, it is used mainly to help people fall asleep, including for awakenings in the middle of the night.